Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 4;10(10):1207.
doi: 10.3390/antibiotics10101207.

Retrospective 8-Year Study on the Antibiotic Resistance of Uropathogens in Children Hospitalised for Urinary Tract Infection in the Emilia-Romagna Region, Italy

Collaborators, Affiliations

Retrospective 8-Year Study on the Antibiotic Resistance of Uropathogens in Children Hospitalised for Urinary Tract Infection in the Emilia-Romagna Region, Italy

Susanna Esposito et al. Antibiotics (Basel). .

Abstract

The development and spread of antibiotic resistance is an increasingly important global public health problem, even in paediatric urinary tract infection (UTI). In light of the variability in the data, it is necessary to conduct surveillance studies to determine the prevalence of antibiotic resistance in specific geographical areas to optimize therapeutic management. In this observational, retrospective, multicentre study, the medical records of 1801 paediatric patients who were hospitalised for UTI between 1 January 2012, and 30 June 2020, in Emilia-Romagna, Italy, were analysed. Escherichia coli was the most frequently detected pathogen (75.6%), followed by Klebsiella pneumoniae (6.9%) and Pseudomonas aeruginosa (2.5%). Overall, 840 cases (46.7%) were due to antimicrobial-resistant uropathogens: 83 (4.7%) extended spectrum beta-lactamase (ESBL)-producing, 119 (6.7%) multidrug resistant (MDR) and 4 (0.2%) extensively drug resistant (XDR) bacteria. Empirical antibiotic therapy failed in 172 cases (9.6%). Having ESBL or MDR/XDR uropathogens, a history of recurrent UTI, antibiotic therapy in the preceding 30 days, and empirical treatment with amoxicillin or amoxicillin/clavulanate were significantly associated with treatment failure, whereas first-line therapy with third-generation cephalosporins was associated with protection against negative outcomes. In conclusion, the increase in the resistance of uropathogens to commonly used antibiotics requires continuous monitoring, and recommendations for antibiotic choice need updating. In our epidemiological context, amoxicillin/clavulanate no longer seems to be the appropriate first-line therapy for children hospitalised for UTI, whereas third-generation cephalosporins continue to be useful. To further limit the emergence of resistance, every effort to reduce and rationalise antibiotic consumption must be implemented.

Keywords: antibiotic therapy; antimicrobial resistance; extended-spectrum beta-lactamase-producing bacteria; extensively drug-resistant bacteria; multidrug resistance; urinary tract infection.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Stephens G.M., Akers S., Nguyen H., Woxland H. Evaluation and management of urinary tract infections in the school-aged child. Prim. Care. 2015;42:33–41. doi: 10.1016/j.pop.2014.09.007. - DOI - PubMed
    1. Korbel L., Howell M., Spencer J.D. The clinical diagnosis and management of urinary tract infections in children and adolescents. Paediatr. Int. Child Health. 2017;37:273–279. doi: 10.1080/20469047.2017.1382046. - DOI - PubMed
    1. Balighian E., Burke M. Urinary Tract Infections in Children. Pediatr. Rev. 2018;39:3–12. doi: 10.1542/pir.2017-0007. - DOI - PubMed
    1. Edlin R.S., Shapiro D.J., Hersh A.L., Copp H.L. Antibiotic resistance patterns of outpatient pediatric urinary tract infections. J. Urol. 2013;190:222–227. doi: 10.1016/j.juro.2013.01.069. - DOI - PMC - PubMed
    1. Khoshnood S., Heidary M., Mirnejad R., Bahramian A., Sedighi M., Mirzaei H. Drug-resistant gram-negative uropathogens: A review. Biomed Pharmacother. 2017;94:982–994. doi: 10.1016/j.biopha.2017.08.006. - DOI - PubMed

LinkOut - more resources